322510.Kq
322510.KQ is a South Korean company operating in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of medical equipment and technology solutions.
Business. 322510.KQ is a South Korean company operating in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of medical equipment and technology solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
322510.KQ is a South Korean company operating in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of medical equipment and technology solutions.
The company's capital structure is characterized by a debt-to-equity ratio of 0.73, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 2.06, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at -12,342,197,500 KRW, and its free cash flow is also negative at -13,276,369,120 KRW, indicating a lack of cash generation from operations.
Profitability metrics show that the company is currently unprofitable, with a net income of -13,605,981,250 KRW and a return on equity of -0.329, which is significantly below the industry median for the Advanced Medical Equipment & Technology sector. The company's return on assets is also negative at -0.1828, further highlighting its poor performance in generating returns from its asset base.
The company's revenue is concentrated in a single geographic region, as disclosed segments do not provide a breakdown of geographic exposure. This lack of geographic diversification may expose the company to regional economic or regulatory risks.
The company's growth trajectory is currently negative, with a net income decline and a negative operating cash flow. The outlook for the current fiscal year indicates a continuation of this trend, with no significant improvement in revenue or profitability expected in the near term.
The company's risk assessment highlights a medium liquidity risk, primarily due to its negative operating and free cash flows. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. The company's capital structure and financial performance suggest a need for careful monitoring of its liquidity and profitability metrics.
Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The company's financial performance and risk profile suggest a need for further analysis of its business strategy and financial management practices.
- The company is currently unprofitable with a net income of -13,605,981,250 KRW and a return on equity of -0.329.
- The company's liquidity position is medium, with a current ratio of 2.06, but it has negative operating and free cash flows.
- The company's capital structure is moderately leveraged, with a debt-to-equity ratio of 0.73.
- The company's growth trajectory is negative, with no significant improvement in revenue or profitability expected in the near term.
- The company's risk assessment highlights a medium liquidity risk and a low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 322510.KQ Market data — financials · 2026-05-26